Agios Pharmaceuticals/ US00847X1046 /
2024-04-17 9:59:54 PM | Chg. +0.27 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
29.03USD | +0.94% | 17,831 Turnover: 519,067.76 |
-Bid Size: - | -Ask Size: - | 29.35 | 28.91 |
GlobeNewswire
1:00 PM
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
GlobeNewswire
03-05
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
GlobeNewswire
02-22
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
GlobeNewswire
02-15
OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer
GlobeNewswire
02-15
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
GlobeNewswire
02-02
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 1...
GlobeNewswire
01-03
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endp...
GlobeNewswire
01-02
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
GlobeNewswire
2023-12-10
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Dis...
GlobeNewswire
2023-11-20
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in...
GlobeNewswire
2023-11-02
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorder...
GlobeNewswire
2023-10-19
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
GlobeNewswire
2023-09-19
Marketing and Finance Leaders Seek Collaboration to Make Smarter Investments, Says CMO Council and K...
GlobeNewswire
2023-08-29
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
GlobeNewswire
2022-03-07
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
GlobeNewswire
2022-02-17
Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolyt...